Janus Kinase Inhibition in Sarcoidosis
NCT05696795
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Sarcoidosis
Interventions
DRUG:
Abrocitinib 200 mg
Sponsor
Yale University
Collaborators
[object Object]